Literature DB >> 18039202

Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan.

Masatoshi Makuuchi1, Norihiro Kokudo, Shigeki Arii, Shunji Futagawa, Shuichi Kaneko, Seiji Kawasaki, Yutaka Matsuyama, Masatoshi Okazaki, Kiwamu Okita, Masao Omata, Yukihisa Saida, Tadatoshi Takayama, Yoshio Yamaoka.   

Abstract

The Clinical Practice Guidelines for Hepatocellular Carcinoma (HCC), the first evidence-based guidelines for the treatment of HCC in Japan, were compiled by an expert panel supported by the Japanese Ministry of Health, Labour, and Welfare. This set of guidelines covers six research fields: prevention, diagnosis and surveillance, surgery, chemotherapy, transarterial chemoembolization, and percutaneous local ablation therapy. A systematic review of the English medical literature on HCC was performed, and a total of 7192 publications were extracted, mainly from MEDLINE (1966-2002). After the second selection, 334 articles were adopted for the guidelines to form 58 pairs of research questions and recommendations. For the users' convenience, practical algorithms for the surveillance and treatment of HCC were also created, which were based on evidence from the selected articles forthe guidelines and modified according to the current status of medical practice in Japan, where liver resection for HCC is regarded as safe with less than 1% mortality and cadaveric donors for liver transplantation are extremely difficult to obtain. The formation of the guidelines and the outline of their contents are described. The Japanese HCC guidelines may be useful in decision making at every clinical step, both for patients and physicians. Although the main users of these guidelines are assumed to be Japanese physicians, the accumulated evidence and interpretation in the guidelines may attract universal attention.

Entities:  

Year:  2008        PMID: 18039202     DOI: 10.1111/j.1872-034X.2007.00216.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  90 in total

1.  Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.

Authors:  Richard K Sterling; Elizabeth C Wright; Timothy R Morgan; Leonard B Seeff; John C Hoefs; Adrian M Di Bisceglie; Jules L Dienstag; Anna S Lok
Journal:  Am J Gastroenterol       Date:  2011-09-20       Impact factor: 10.864

2.  Autoimmune hepatitis, cirrhosis, and hepatocellular carcinoma (HCC).

Authors:  Palak Jitendrakumar Trivedi; Sue Cullen
Journal:  Dig Dis Sci       Date:  2011-02       Impact factor: 3.199

3.  Surgical and Locoregional Therapy of HCC: TACE.

Authors:  Masakatsu Tsurusaki; Takamichi Murakami
Journal:  Liver Cancer       Date:  2015-07-10       Impact factor: 11.740

Review 4.  Role of surgical resection for hepatocellular carcinoma based on Japanese clinical guidelines for hepatocellular carcinoma.

Authors:  Hisashi Nakayama; Tadatoshi Takayama
Journal:  World J Hepatol       Date:  2015-02-27

Review 5.  Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis.

Authors:  Kerstin Schütte; Christian Schulz; Alexander Link; Peter Malfertheiner
Journal:  World J Hepatol       Date:  2015-02-27

6.  A Novel Noninvasive Method for Predicting Liver Fibrosis by Quantifying the Estrangement of Indocyanine Green Retention Rate and Tc-99m-diethylenetriamine-penta-acetic Acid-galactosyl Human Serum Albumin Scintigraphy.

Authors:  Takehiko Hanaki; E I Uchinaka; Takuki Yagyu; Masaki Morimoto; Joji Watanabe; Kozo Miyatani; Kyoichi Kihara; Tomoyuki Matsunaga; Manabu Yamamoto; Yoji Fukumoto; Naruo Tokuyasu; Shuichi Takano; Teruhisa Sakamoto; Soichiro Honjo; Toshimichi Hasegawa; Yoshiyuki Fujiwara
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

7.  Alcohol, postprandial plasma glucose, and prognosis of hepatocellular carcinoma.

Authors:  Hiroshi Abe; Yuta Aida; Haruya Ishiguro; Kai Yoshizawa; Tamihiro Miyazaki; Munenori Itagaki; Satoshi Sutoh; Yoshio Aizawa
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

8.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

9.  Could radiofrequency ablation replace liver resection for small hepatocellular carcinoma in patients with compensated cirrhosis? A 5-year follow-up.

Authors:  Jacopo Desiderio; Stefano Trastulli; Rosario Pasquale; Davide Cavaliere; Roberto Cirocchi; Carlo Boselli; Giuseppe Noya; Amilcare Parisi
Journal:  Langenbecks Arch Surg       Date:  2012-12-07       Impact factor: 3.445

10.  Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines.

Authors:  Norihiro Kokudo; Masatoshi Makuuchi
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.